|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.08.25 - 23:03
|
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer (Business Wire)
|
|
|
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan.
Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands.
“Nathan's deep financial expertise in molecular diagnostics is a great fit for CareDx,” said John Hanna, CEO of CareDx. “His track record of operational excellence and experience in supporting diagnostics companies to scale efficiently will be invaluable as we enter our next phase.”
In co...
|
|
|
06.08.25 - 15:25
|
Pre-market Movers: MYGN, LFMD, EOLS, LNTH, ALAB. (AFX)
|
|
|
OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.15 A.M. ET).In the Green Myriad Genetics, Inc. (MYGN) is up over 30% at $5.04. ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.07.25 - 22:09
|
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025 (GlobeNewswire EN)
|
|
|
SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the second quarter 2025....
|
|
|
15.07.25 - 15:03
|
Myriad Genetics Earns 2025 Great Place To Work Certification™ (GlobeNewswire EN)
|
|
|
SALT LAKE CITY, July 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has received the Great Place to Work Certification for the third year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said Myriad Genetics is a Great Place To Work – 30 percentage points higher than the average U.S. company....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
